Estrella Immunopharma (ESLA) Competitors $0.88 -0.06 (-6.38%) Closing price 04:00 PM EasternExtended Trading$0.89 +0.01 (+0.80%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ESLA vs. SCPH, ACTU, NKTX, CGEN, OGI, TLSA, GLSI, DERM, MCRB, and ALECShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include scPharmaceuticals (SCPH), Actuate Therapeutics (ACTU), Nkarta (NKTX), Compugen (CGEN), Organigram (OGI), Tiziana Life Sciences (TLSA), Greenwich LifeSciences (GLSI), Journey Medical (DERM), Seres Therapeutics (MCRB), and Alector (ALEC). These companies are all part of the "pharmaceutical products" industry. Estrella Immunopharma vs. scPharmaceuticals Actuate Therapeutics Nkarta Compugen Organigram Tiziana Life Sciences Greenwich LifeSciences Journey Medical Seres Therapeutics Alector Estrella Immunopharma (NASDAQ:ESLA) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, community ranking, institutional ownership, profitability and media sentiment. Does the media favor ESLA or SCPH? In the previous week, Estrella Immunopharma's average media sentiment score of 0.00 equaled scPharmaceuticals'average media sentiment score. Company Overall Sentiment Estrella Immunopharma Neutral scPharmaceuticals Neutral Do insiders and institutionals hold more shares of ESLA or SCPH? 0.3% of Estrella Immunopharma shares are held by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are held by institutional investors. 55.1% of Estrella Immunopharma shares are held by company insiders. Comparatively, 5.5% of scPharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has higher valuation & earnings, ESLA or SCPH? Estrella Immunopharma has higher earnings, but lower revenue than scPharmaceuticals. Estrella Immunopharma is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/A-$7.31M-$0.26-3.38scPharmaceuticals$36.33M3.21-$54.81M-$1.90-1.22 Which has more volatility and risk, ESLA or SCPH? Estrella Immunopharma has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Does the MarketBeat Community favor ESLA or SCPH? scPharmaceuticals received 162 more outperform votes than Estrella Immunopharma when rated by MarketBeat users. However, 100.00% of users gave Estrella Immunopharma an outperform vote while only 67.08% of users gave scPharmaceuticals an outperform vote. CompanyUnderperformOutperformEstrella ImmunopharmaOutperform Votes1100.00% Underperform VotesNo VotesscPharmaceuticalsOutperform Votes16367.08% Underperform Votes8032.92% Do analysts prefer ESLA or SCPH? Estrella Immunopharma presently has a consensus target price of $16.00, suggesting a potential upside of 1,718.18%. scPharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 503.45%. Given Estrella Immunopharma's higher possible upside, research analysts clearly believe Estrella Immunopharma is more favorable than scPharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00scPharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ESLA or SCPH more profitable? Estrella Immunopharma has a net margin of 0.00% compared to scPharmaceuticals' net margin of -264.60%. Estrella Immunopharma's return on equity of -195.77% beat scPharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A -195.77% -157.28% scPharmaceuticals -264.60%-244.93%-68.56% SummaryEstrella Immunopharma beats scPharmaceuticals on 8 of the 14 factors compared between the two stocks. Remove Ads Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLA vs. The Competition Export to ExcelMetricEstrella ImmunopharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.83M$2.83B$5.28B$7.07BDividend YieldN/A1.53%4.87%4.05%P/E Ratio-3.3829.1822.8717.48Price / SalesN/A420.20357.3785.27Price / CashN/A168.6838.1634.64Price / Book7.333.496.233.79Net Income-$7.31M-$72.06M$3.20B$247.10M7 Day Performance-7.27%-12.86%-7.91%-7.31%1 Month Performance-13.73%-20.18%-2.94%-10.19%1 Year Performance-22.81%-34.28%3.18%-7.40% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAEstrella Immunopharma1.8561 of 5 stars$0.88-6.4%$16.00+1,718.2%-25.8%$31.83MN/A-3.38N/AGap DownSCPHscPharmaceuticals3.3417 of 5 stars$2.63-5.4%$14.00+432.3%-55.9%$132.25M$36.33M-1.3830Gap DownHigh Trading VolumeACTUActuate TherapeuticsN/A$6.77-14.3%$20.00+195.4%N/A$132.23MN/A0.0010Gap DownNKTXNkarta2.482 of 5 stars$1.84-8.0%$14.86+707.5%-82.0%$130.56MN/A-0.98140Gap DownCGENCompugen1.2085 of 5 stars$1.46-4.6%$4.00+174.0%-42.0%$130.29M$27.86M73.0070Gap DownOGIOrganigram0.5307 of 5 stars$1.01-1.9%N/A-57.2%$127.52M$166.12M-2.66860Gap DownTLSATiziana Life Sciences0.7423 of 5 stars$1.08-3.6%N/A+133.7%$126.20MN/A0.008Gap DownGLSIGreenwich LifeSciences1.5789 of 5 stars$9.54-6.7%$38.00+298.3%-47.8%$125.40MN/A-11.923News CoverageGap DownDERMJourney Medical2.4309 of 5 stars$5.90-3.4%$9.67+63.8%+92.7%$123.25M$56.13M-6.2890Gap DownMCRBSeres Therapeutics3.0996 of 5 stars$0.70-2.9%$4.00+471.3%-5.2%$122.07M$126.33M-3.04330Positive NewsALECAlector3.6465 of 5 stars$1.23-4.7%$3.50+184.6%-81.5%$121.88M$100.56M-0.72270Gap Down Remove Ads Related Companies and Tools Related Companies scPharmaceuticals Competitors Actuate Therapeutics Competitors Nkarta Competitors Compugen Competitors Organigram Competitors Tiziana Life Sciences Competitors Greenwich LifeSciences Competitors Journey Medical Competitors Seres Therapeutics Competitors Alector Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESLA) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
